Early Stage Devices For Rare Conditions Receive FDA Funding
This article was originally published in The Gray Sheet
Executive Summary
An early intervention to treat scoliosis and a test for diagnosing eosinophilic esophagitis were among the innovations FDA supported Oct. 21, when it announced the recipients of 15 grants worth more than $14 million and focused on rare disease treatment.
You may also be interested in...
No Devices on FDA Orphan Research Grant List
The agency has used the grant to support development of devices for rare diseases in the past, but this year the list of grant recipients does not include any funding for device research.
FDA Tackles Shortage Of Child-Friendly Devices With Pediatric Consortia Funds
Seven pediatric device consortia received grants from FDA worth $18 million to promote growth in the underdeveloped pediatric device market.
Device Investors Showing Some Spine
This clearly isn’t the go-go period of spine in the mid 2000s, but venture capitalists can’t ignore the enormous opportunities for companies able to treat low back pain. Elsevier’s Strategic Transactions shows that just in the last year, 26 spine or low back pain companies received private funding. To be sure, many were small rounds, some were funded with debt, and some were insider rounds trying to keep companies moving forward, but venture investors showed excitement by investing in large rounds for a select number of start-ups.